CEO SUMMARY: Pathologists and clinical lab managers interested in following the advances in use of whole human genome sequencing for clinical purposes should follow the money. Within weeks of obtaining FDA clearance for its MiSeqDx system and reagents, Illumina had inked major agreements with Quest Diagnostics Incorporated and Laboratory Corporation of America. Both national lab […]
Whole Genome Sequencing Is Poised for Clinical Use
After FDA cleared Illumina’s gene sequencing system and reagents, two Blood Brothers moved fast
- By Robert Michel
- > From the Volume XXI No. 5 - April 7, 2014 Issue
- Tags: Anatomic pathology, anatomic pathology services, cap, clinical lab, clinical lab manager, clinical lab test, clinical lab tests, clinical laboratories, clinical labs, clinical trials, cost of sequencing, diagnostic lab, diagnostic labs, dna sequence, dna sequencing, FDA Clearance, gene sequence, gene sequences, gene sequencing, gene sequencing service, gene sequencing technology, generation sequencing, genome sequencing, genomics, human genome, human genome sequencing, impac, lab administrator, lab manager, lab managers, lab test, lab tests, laboratories, ldt, molecular lab, molecular laboratory, molecular tests, next-generation gene sequencing, pathologists, Pathology group, pathology groups, pathology service, pathology services, personalized medicine, quest diagnostics and labcorp, sequencing cost, sequencing costs, sequencing devices, sequencing service, sequencing services, sequencing technology, whole human genome sequencing
